01:24 PM EST - HAVN Life Sciences : Announced it has entered into a definitive agreement to acquire all of the outstanding securities of Spore Life Sciences Inc., on the terms and conditions set forth in the Definitive Agreement. Toronto-based Spore Life Sciences Inc. is a leading wellness brand focused on functional mushroom formulations, with a significant U.S. consumer base of more than 110,000 Spore customers, nearly 40,000 subscribers, resulting in year to date revenues as of the end of November 2021 of nearly CAD$8 million, and current sales of more than $1 million USD per month. HAVN Life Sciences
shares C.HAVN are trading unchanged at $0.17.
